Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Community-Acquired Clostridium difficile Infection, Queensland, Australia.
Furuya-Kanamori L, Yakob L, Riley TV, Paterson DL, Baker P, McKenzie SJ, Robson J, Clements AC. Furuya-Kanamori L, et al. Emerg Infect Dis. 2016 Sep;22(9):1659-61. doi: 10.3201/eid2209.151115. Emerg Infect Dis. 2016. PMID: 27533328 Free PMC article. No abstract available.
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. Harris PN, et al. Trials. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9. Trials. 2015. PMID: 25623485 Free PMC article. Clinical Trial.
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Harris PNA, et al. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. JAMA. 2018. PMID: 30208454 Free PMC article. Clinical Trial.
The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication.
Baker PJ, Bohrer AC, Castro E, Amaral EP, Snow-Smith M, Torres-Juárez F, Gould ST, Queiroz ATL, Fukutani ER, Jordan CM, Khillan JS, Cho K, Barber DL, Andrade BB, Johnson RF, Hilligan KL, Mayer-Barber KD. Baker PJ, et al. bioRxiv [Preprint]. 2024 Mar 27:2024.03.27.586885. doi: 10.1101/2024.03.27.586885. bioRxiv. 2024. PMID: 38585846 Free PMC article. Preprint.
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2.
Hilligan KL, Namasivayam S, Clancy CS, Baker PJ, Old SI, Peluf V, Amaral EP, Oland SD, O'Mard D, Laux J, Cohen M, Garza NL, Lafont BAP, Johnson RF, Feng CG, Jankovic D, Lamiable O, Mayer-Barber KD, Sher A. Hilligan KL, et al. Among authors: baker pj. Nat Commun. 2023 Dec 12;14(1):8229. doi: 10.1038/s41467-023-43447-0. Nat Commun. 2023. PMID: 38086794 Free PMC article.
500 results